United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 9

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 9 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderCerus · 41

Strongest available pathLensAR · +10.6%

Widest latest marginCerus · -6.7%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1CERS · Nasdaq

Cerus

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1991Concord, California$526.0M market cap

View full Companies Radar profile

41Cautious

Snapshot price$2.61as of page date

Monthly-close return-57.1%five-year window

FY2025 revenue$0.23BCERUS CORP

Net margin-6.7%FY2025

P/E snapshot-522.0xone ratio, not a verdict

Prism attention36.2%share across these five

Filing track recordRevenue, USD billions

+46.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 10.0%

52-week position63% through range

$1.17$3.47

News mentions1.1K

Community mentions0partial coverage

U.S.-scope patents389

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2LNSR · Nasdaq

LensAR

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2004Orlando, Florida$103.9M market cap

View full Companies Radar profile

41Cautious

Snapshot price$8.46as of page date

Monthly-close return+10.6%five-year window

FY2025 revenue$0.05BLENSAR, Inc.

Net margin-66.4%FY2025

P/E snapshot42.3xone ratio, not a verdict

Prism attention13.8%share across these five

Filing track recordRevenue, USD billions

+75.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 15.0%

52-week position44% through range

$4.95$12.94

News mentions415

Community mentions4partial coverage

U.S.-scope patents377

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal55/100
Management stability90/100
Market position15/100
Capital-event signal29/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 3 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3LUNG · Nasdaq

Pulmonx

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1998Redwood City, California$94.6M market cap

View full Companies Radar profile

41Cautious

Snapshot price$2.24as of page date

Monthly-close return-93.8%five-year window

FY2025 revenue$0.09BPulmonx Corp

Net margin-59.7%FY2025

P/E snapshot-2.4xone ratio, not a verdict

Prism attention11.3%share across these five

Filing track recordRevenue, USD billions

+86.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 16.9%

52-week position63% through range

$1.13$2.89

News mentions338

Community mentions4partial coverage

U.S.-scope patents313

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal44/100
Management stability90/100
Market position0/100
Capital-event signal60/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 4 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4SINT · Nasdaq

SINTX

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1996Salt Lake City$9.9M market cap

View full Companies Radar profile

41Cautious

Snapshot price$1.49as of page date

Monthly-close return-100.0%five-year window

FY2025 revenue$0.00BSintx Technologies, Inc.

Net margin-1018.1%FY2025

P/E snapshot-1.2xone ratio, not a verdict

Prism attention11.9%share across these five

Filing track recordRevenue, USD billions

+68.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 13.8%

52-week position2% through range

$1.40$6.78

News mentions358

Community mentions34partial coverage

U.S.-scope patents173

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal32/100
Management stability90/100
Market position6/100
Capital-event signal72/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 1 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5NPCE · Nasdaq

NeuroPace

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1997Mountain View, California$505.9M market cap

View full Companies Radar profile

40Cautious

Snapshot price$14.74as of page date

Monthly-close return-7.0%five-year window

FY2025 revenue$0.10BNeuroPace Inc

Net margin-21.5%FY2025

P/E snapshot-66.3xone ratio, not a verdict

Prism attention26.8%share across these five

Filing track recordRevenue, USD billions

+121.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.0%

52-week position55% through range

$8.88$19.60

News mentions804

Community mentions19partial coverage

U.S.-scope patents376

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position0/100
Capital-event signal45/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

LensAR

+10.6%

NeuroPace

-7.0%

Cerus

-57.1%

Pulmonx

-93.8%

SINTX

-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

Cerus

$0.23B

NeuroPace

$0.10B

Pulmonx

$0.09B

LensAR

$0.05B

SINTX

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Cerus

-6.7%

NeuroPace

-21.5%

Pulmonx

-59.7%

LensAR

-66.4%

SINTX

-1018.1%

Prism news attention

Normalized share across these five names; attention is not quality.

Cerus

36.2%

NeuroPace

26.8%

LensAR

13.8%

SINTX

11.9%

Pulmonx

11.3%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Cerus leads the conversation

It holds 36.2% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.23B.

Price path

LensAR leads the available price paths

Its monthly-close return is +10.6% for the five-year window. At the other end, SINTX is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Cerus has the widest latest margin

Its FY2025 net margin is -6.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Cerus shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -522.0x while its five-year window price return is -57.1%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · CERS

Cerus

1,085available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-65.0%92 latest 12m vs 263 prior 12m

Machine-classified coverage tone

84.9% positive+2.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 19stock surge 17stock price 15share price 13earnings report 9initial public offering 8stock market debut 8ipo pricing 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-06-12 · trend and themes shown through 2026-06

Areas of research · NPCE

NeuroPace

804available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Macro demand & rates

Leadership & governance

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+33.6%179 latest 12m vs 134 prior 12m

Machine-classified coverage tone

92.8% positive-1.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 20stock price 12responsive neurostimulation epilepsy 11earnings report 11epilepsy neuromodulation 9status epilepticus management 8seizure management 8stereoencephalography epilepsy 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-14–2026-06-04 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

SINT

SINTX

34 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 34 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

CERS

Cerus

through 2025-06-10

Earnings releases 2Listing / IPO 2Regulatory 1

2025-06-10
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $185.14 million 1.49 -$37.49 million ($0.10) -14.40
2025-02-14
Listing / IPO
Cerus raised $57.78M in a public offering. The underwriter has an overallotment option on 900,000 shares.
2023-06-05
Regulatory
Cerus received a $5-million cash milestone payment from BioOne triggered by the CE mark regulatory approval for its INTERCEPT Blood System for plasma in Europe.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LNSR

LensAR

through 2026-04-15

Earnings releases 20M&A 2

2026-04-15
Earnings releases
Total revenue for the quarter ended December 31, 2025 decreased by approximately $0.7 million, or 4%, compared to the fourth quarter of 2024.
2025-03-24
M&A
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and LENSAR, Inc. (NASDAQ: LNSR), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire LENSAR.
2026-04-15
Earnings releases
Total revenue - 58,435 - 53,494

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LUNG

Pulmonx

through 2025-11-13

Earnings releases 13Leadership changes 4

2025-11-13
Earnings releases
contributing to a net loss of $14 million.
2025-10-27
Leadership changes
Steve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediately.
2025-10-27
Leadership changes
Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the reappointment of Glen French as President and Chief Executive Officer, effective immediately, and the appointment of Derrick Sung as Chief Operating Officer and Chief Financial Officer, effective November 3, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SINT

SINTX

through 2026-04-14

Leadership changes 14Earnings releases 9Business contracts 3Asset acquisitions 1Company announcements 1

2026-04-14
Earnings releases
Ascendiant Capital Markets also issued estimates for Sintx Technologies’ Q3 2027 earnings at ($0.47) EPS.
2026-02-02
Leadership changes
SINTX announces promotion of David O’Brien to chief operating officer SINTX Technologies, an OEM ceramics company, announced the promotion of David O’Brien to chief operating officer.
2025-06-25
Asset acquisitions
SINTX Technologies, Inc. (NASDAQ: SINT), a Salt Lake City-based advanced ceramics company, acquired the surgical business assets of SiNAPTIC Holdings, LLC, a privately held silicon nitride ceramic manufacturer, in an all-equity transaction valued at $750,000 in common shares.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NPCE

NeuroPace

through 2026-03-22

Earnings releases 31Leadership changes 5

2026-03-22
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99 million 4.38 -$21.47 million ($0.66) -19.70 OPKO Health $606.90 million 1.40 -$225.68 million ($0.30) -3.73
2025-02-13
Leadership changes
Ms. Kumar also serves as a director and as chair of the audit committee for NeuroPace (NASDAQ: NPCE), a medical device company dedicated to reducing debilitating seizures in patients with epilepsy.
2026-01-27
Earnings releases
NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 41–48. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Cerus leads the readiness ranking

Its Prism readiness score is 41/100, the highest in this five-company comparison.

Open Cerus in Companies Radar

Scale and margin leadership sit with Cerus and Cerus

Cerus has the largest displayed latest revenue at $0.23B; Cerus has the widest displayed latest margin at -6.7%.

Open Cerus in Companies Radar

Comparisons

Strongest versus weakest available price path

LensAR is +10.6% for its five-year window; SINTX is -100.0% for its five-year window.

Open LensAR in Companies Radar Open SINTX in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.23B for Cerus to $0.00B for SINTX. Entity and filing-period labels remain visible on the company cards.

Open Cerus in Companies Radar Open SINTX in Companies Radar

Anomalies

NeuroPace has the widest attention-readiness rank gap

It ranks #2 by measured news attention (26.8%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open NeuroPace in Companies Radar

Pulmonx shows a price-operating divergence to inspect

Its displayed filing-revenue change is +86.9% while its available monthly-close return is -93.8%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Pulmonx in Companies Radar

Explanations

Attention measures coverage volume, not quality

Cerus's 36.2% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Cerus in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Cerus's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 41/100 score.

Open Cerus in Companies Radar

Stress-test the largest divergence before forming a view

Compare Pulmonx's profile with LensAR's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Pulmonx in Companies Radar Open LensAR in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.